Vedanta's CDI product VE303 well tolerated in Phase I

Vedanta Biosciences Inc. (Cambridge, Mass.) said single and multiple ascending doses of VE303

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE